Edgewise Therapeutics Reports Positive Phase 2 Data for Cardiac Sarcomere Modulator EDG-7500 in Hypertrophic Cardiomyopathy
Key Insights
Edgewise Therapeutics reported positive updates from its ongoing CIRRUS-HCM Phase 2 trial of EDG-7500, an oral cardiac sarcomere (search) modulator for hypertrophic cardiomyopathy (search).
The 25 mg dose cohort demonstrated clinical activity across key HCM disease markers while maintaining a favorable safety profile with no clinically meaningful changes in left ventricular ejection fraction.
The company remains on track to deliver comprehensive efficacy and safety data from Part D in Q2 2026 and plans Phase 3 trial initiation by end of 2026.
Edgewise Therapeutics reported positive interim updates from its ongoing CIRRUS-HCM Phase 2 clinical trial of EDG-7500, an oral cardiac sarcomere (search) modulator being developed for hypertrophic cardiomyopathy (search) (HCM). The announcement drove the company's stock up nearly 20% on Wednesday, reflecting investor confidence in the drug's therapeutic potential.
Trial Design and Patient Population
EDG-7500 is specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM without impacting systolic function. The CIRRUS-HCM trial has enrolled a total of 43 participants across all dose groups in Parts B and C, which have now completed dosing.
In addition to the previously reported 50 mg and 100 mg fixed doses, the company evaluated a lower 25 mg fixed dose in 4 obstructive HCM (oHCM) and 10 non-obstructive HCM (nHCM) participants in Parts B and C, respectively.
Safety and Efficacy Results
The 25 mg dose cohort demonstrated evidence of clinical activity across key HCM disease markers while maintaining a favorable safety profile. Notably, there were no clinically meaningful changes in left ventricular ejection fraction (LVEF) or reductions in LVEF to below 50%, and no events of atrial fibrillation (search) were observed.
The ongoing Part D of the trial is designed to explore exposure-response correlations, assess biomarker-guided dose optimization to inform Phase 3 trial design, and support regulatory discussions. In an interim safety update covering 20 participants who completed 12 weeks of dosing in Part D (8 with oHCM and 12 with nHCM), EDG-7500 demonstrated a generally favorable safety profile and was well tolerated.
Differentiated Safety Profile
Consistent with previous observations, no clinically significant changes in LVEF or reductions in LVEF to below 50% were observed in Part D. The company emphasized that EDG-7500 continues to demonstrate a differentiated LVEF profile relative to cardiac myosin inhibitors (CMIs), a competing class of HCM treatments.
The safety profile observed with EDG-7500 across both healthy volunteers and the CIRRUS-HCM trial supports the potential use of the drug in diverse HCM patient populations.
Development Timeline and Competitive Context
Edgewise remains on track to deliver comprehensive efficacy and safety data from Part D of the CIRRUS-HCM trial in the second quarter of 2026. The company is advancing Phase 3 trial design in preparation for trial initiation by the end of 2026.
The positive update comes shortly after the FDA approved Cytokinetics (search)' Myqorzo (search) (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (search) to improve functional capacity and symptoms, highlighting the competitive landscape in HCM therapeutics.
Market Response
The positive trial update drove significant investor interest, with Edgewise Therapeutics shares jumping 19.94% to $26.08 on Wednesday. Trading volume reached approximately 2.36 million shares, nearly double the average volume of 1.29 million shares, indicating heightened market attention to the company's HCM program.